Verona Pharma plc Sponsored ADR Forecast, price target & analysts
Verona Pharma plc Sponsored ADR Target price 2025 - Analyst rating & recommendation
Verona Pharma plc Sponsored ADR Classifications & Recommendation:
Verona Pharma plc Sponsored ADR Price Target
| Target Price | $92.36 |
| Price | $74.73 |
| Potential |
23.60%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2026 .
The average Verona Pharma plc Sponsored ADR target price is $92.36.
This is
23.60%
register free of charge
$107.00
43.18%
register free of charge
$75.00
0.36%
register free of charge
|
|
| A rating was issued by 11 analysts: 11 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2026 of
23.60%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.28 | 403.88 |
| 854.79% | ||
| EBITDA Margin | -363.22% | 26.04% |
| 107.17% | ||
| Net Margin | -54.36% | 5.90% |
| 101.38% |
11 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2025. The average Verona Pharma plc Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.27 | 0.28 |
| 200.00% | 113.15% | |
| P/E | 266.89 | |
| EV/Sales | 15.36 |
4 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Verona Pharma plc Sponsored ADR...
Current Verona Pharma plc Sponsored ADR Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
| Roth MKM |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
|
Locked
Roth MKM:
Locked
➜
Locked
|
Jan 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
